Patient Death Prompts MacroGenics To Close Mid-Stage Head & Cancer Study

MacroGenics Inc  (NASDAQ: MGNX ) closed the Phase 2 study  (CP-MGA271-06) of enoblituzumab in the first-line treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). The trial evaluated the regimen of enoblituzumab in combination with either retifanlimab or tebotelimab. The decision to discontinue ... Full story available on Benzinga.com